MF59 clinical trials
Also written MF59.
How each study uses MF59 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MF59 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 19
National Institute of Allergy and Infectious Diseases (NIAID) (9) · Novartis Vaccines (6) · Korea University Guro Hospital (2) · Seqirus (2) · Biomedical Advanced Research and Development Authority (2) · Novartis (2) · The University of Hong Kong (1) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (5) · AS03 (2) · DNA-HIV-PT123 (2) · Proteins (2) · HIV Envelope Protein gp120 (1) · Amilomotide (1) · AS03 adjuvant (1) · GP 140 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test MF59, phase 3 first.
- Apr 2027Influenza Vaccination Strategy for Patients With Hematologic MalignancyPhase 3 · Asan Medical Center
- Dec 2026Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical TrialNot applicable · National Taiwan University Hospital
Studies
Open first, then newest update. How each study uses MF59 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 30
- Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older AdultsRecruitingPhase 4Korea University Guro HospitalNCT07838298Written as MF59 adjuvanted influenza vaccine
- Influenza Vaccination Strategy for Patients With Hematologic MalignancyRecruitingPhase 3Asan Medical CenterNCT07485855Written as MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)
- Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical TrialNot yet recruitingNot applicableNational Taiwan University HospitalNCT07126652Written as MF-59
- Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older AdultsCompletedPhase 4Korea University Guro HospitalNCT07805837Written as MF59-Adjuvanted Influenza Vaccine
- Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong KongCompletedPhase 4The University of Hong KongNCT03330132Written as MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
- H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03014310Written as MF59
- Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected AdultsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02915016Written as Bivalent Subtype C gp120/MF59 vaccine
- A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000832Written as MF59
- Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01097096Written as MF59
- Reducing the Burden of Influenza After Solid-Organ TransplantationCompletedPhase 2/3Oriol ManuelNCT03699839Written as MF59-adjuvanted influenza vaccine
- Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsCompletedPhase 3SeqirusNCT03314662Written as MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
- Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59CompletedPhase 2Biomedical Advanced Research and Development AuthorityNCT03497845Written as MF59 adjuvant
- Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of AgeCompletedPhase 3SeqirusNCT02587221Written as MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
- Panblok H7 Vaccine Adjuvanted With AS03 or MF59CompletedPhase 2Biomedical Advanced Research and Development AuthorityNCT03283319Written as MF59
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus VaccineCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02251288Written as MF59 adjuvant
- Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy AdultsCompletedPhase 1HIV Vaccine Trials NetworkNCT01418235Written as MVA-C + gp140/MF59
- Safety and Immune Response to a Clade C DNA HIV VaccineCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02997969Written as Protein/MF59 vaccine
- gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent FemalesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00133497Written as MF-59
- H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02213354Written as MF59
- Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedPhase 2/3Novartis VaccinesNCT00996307Written as MF59-eH1N1_f
See all 30 studies that test MF59 →
Given beside what is tested · 8 — MF59 is usual care or a partner of the new treatment
- Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03682120Written as MF59
- H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02624219Written as MF59 adjuvant
- H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01942265Written as MF59
- H7N9 Mix and Match With MF59 in Healthy AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01938742Written as MF59
- H5 Adult - Chiron Study of Bird Flu VaccineCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00280033Written as MF-59
- Recombinant CMV gB Vaccine in Postpartum WomenCompletedPhase 2Robert Pass, MDNCT00125502Written as MF59 adjuvant
- B-19 Parvovirus Vaccine StudyTerminatedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00379938Written as MF-59
- Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory AdultsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00133471Written as MF59 adjuvant
As the comparator · 3 — what is tested is compared with MF59
- Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingPhase 1Ab&B Bio-tech Co., Ltd.JSNCT07421050Written as MF59
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderActive, not recruitingPhase 1Ab&B Bio-tech Co., Ltd.JSNCT07421037Written as MF59
- Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water EmulsionWithdrawnPhase 1Bill & Melinda Gates Medical Research InstituteNCT05035680Written as MF59 adjuvanted seasonal influenza vaccine